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AbstrAct
Restoration of the p53 pathway, namely by reactivation of mutant (mut) p53, 
represents a valuable anticancer strategy. Herein, we report the identification 
of the enantiopure tryptophanol-derived oxazoloisoindolinone SLMP53-1 as a 
novel reactivator of wild-type (wt) and mut p53, using a yeast-based screening 
strategy. SLMP53-1 has a p53-dependent anti-proliferative activity in human wt 
and mut p53R280K-expressing tumor cells. Additionally, SLMP53-1 enhances p53 
transcriptional activity and restores wt-like DNA binding ability to mut p53R280K.  
In wt/mut p53-expressing tumor cells, SLMP53-1 triggers p53 transcription-
dependent and mitochondrial apoptotic pathways involving BAX, and wt/mut 
p53 mitochondrial translocation. SLMP53-1 inhibits the migration of wt/mut  
p53-expressing tumor cells, and it shows promising p53-dependent synergistic effects 
with conventional chemotherapeutics. In xenograft mice models, SLMP53-1 inhibits 
the growth of wt/mut p53-expressing tumors, but not of p53-null tumors, without 
apparent toxicity. Collectively, besides the potential use of SLMP53-1 as anticancer 
drug, the tryptophanol-derived oxazoloisoindolinone scaffold represents a promissing 
starting point for the development of effective p53-reactivating drugs.
IntroductIon
The p53 transcription factor finely regulates the 
expression of genes with central roles in cellular processes 
including DNA repair, cell cycle, and apoptosis [1, 2]. 
Compelling evidence has demonstrated that inactivation 
of the p53 pathway is required for tumor development 
and maintenance. In fact, in all human cancers bearing 
p53, this protein is inactivated by binding to endogenous 
inhibitors, such as murine double minute (MDM)2, 
or by mutation of the TP53 gene [1, 2]. Therefore, p53 
reactivation represents a highly effective strategy in cancer 
treatment [1].
The majority of p53 mutations are missense, 
preferentially localized in the DNA binding domain. They 
can be classified as structural (e.g., R175H, Y220C) or 
DNA contact (e.g., R273H, R280K) based on whether 
or not they lead to a profound protein conformational 
change, respectively. However, both types of mutations 
prevent the p53 binding to DNA, leading to the loss of 
wild-type (wt) p53 transcriptional activity [1–4]. 
Additionally, TP53 mutations may lead to the acquisition 
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of gain-of-function (GOF) activities, responsible for more 
aggressive tumor phenotypes with increased invasive 
and metastatic potential, high chemoresistance, and poor 
prognosis [3–5]. Moreover, high levels of mutant (mut) 
p53 are often found in tumors due to a reduced MDM2 
expression, and consequent impairment of p53 degradation 
[3]. Collectively, these observations support that mut p53 
is a promising therapeutic target against a wide range of 
aggressive tumors [3–5]. 
To date, few small-molecule reactivators of mut p53 
have been identified. Actually, due to its structural nature, 
the restoration of wt-like function to mut p53 has been 
challenging. Moreover, for most of the reported mut p53 
reactivators, unfavorable pharmacokinetics and toxicity 
profiles have been described [6]. In fact, so far, only the 
PRIMA-1 derivative, APR-246, has reached clinical trials 
[1–3]. Therefore, more pharmacological alternatives for 
mut p53 reactivation are still required.
In this work, the enantiopure tryptophanol-derived 
oxazoloisoindolinone SLMP53-1 (Figure 1A) was 
identified as a new reactivator of wt and mut p53R280K. 
This compound revealed in vitro and in vivo p53-dependent 
antitumor activity, both alone and combined with 
conventional chemotherapeutics, against tumors bearing 
wt/mut p53.
results
Identification of SLMP53-1 as activator of wt p53 
and reactivator of mut p53R280K from a yeast 
screening of a library of tryptophanol-derived 
oxazoloisoindolinones
A yeast-based screening assay, consisting of 
Saccharomyces cerevisiae cells expressing human wt 
p53 or mut p53 (R280K or Y220C; two of the most 
prevalent forms of human mut p53 [7]), was developed 
to search for mut p53 reactivators (Figure 1B). This assay 
was established based on the yeast growth inhibitory 
effect induced by wt p53, but not by mut p53 [8]. Based 
on this phenotypic readout, mut p53 reactivators would 
reestablish the wt p53-dependent growth inhibition. Since, 
to date, mut p53R280K reactivators remain unknown, the 
mut p53Y220C reactivator PhiKan083 [9] was used to 
attest the efficacy of the yeast assay (Figure 1B). In yeast, 
50 µM PhiKan083 restored the wt p53-induced growth 
inhibition to mut p53Y220C (in about 63%; Figure 1B). 
This yeast assay was thereafter used to evaluate the 
effect of synthesized enantiopure tryptophanol-derived 
oxazoloisoindolinones on wt and mut p53 activity. These 
compounds were synthesized following our interest in 
enantiopure biologically active amino alcohol-derived 
compounds [10–12], and on our previous discovery 
of phenylalaninol-derived oxazoloisoindolinones with 
in vitro p53-dependent antitumor activity [10]. With this 
new library, we intended to study the effect on p53 activity 
of the replacement of the phenyl moiety (present in our 
first set of compounds [10]) by an indole moiety. Among 
the compounds tested, SLMP53-1 behaved as an activator 
of wt p53 and reactivator of mut p53R280K (Figure 1B 
and 1C). Actually, at 10 µM (lowest concentration, from 
a range of 1–50 µM, that caused a maximal effect; data 
not shown), SLMP53-1 increased the wt p53-induced yeast 
growth inhibition and restored the wt-like growth inhibitory 
effect to mut p53R280K (in about 79%; Figure 1B), 
without interfering with the growth of control yeast (data 
not shown). Consistently, 10 µM SLMP53-1 increased the 
S- and G2/M-phases cell cycle arrest in wt p53-expressing 
yeast, and reestablished the wt-like cell cycle arrest in mut 
p53R280K-expressing yeast (Figure 1C). Interestingly, 
1–50 µM SLMP53-1 did not interfere with the growth of 
mut p53Y220C-expressing yeast (Figure 1B). 
A previous work [13] corroborated the conservation 
in yeast of the p53 transcriptional activity, and established 
its correlation with p53-induced growth inhibition using 
pifithrin-α (PFT-α; known selective inhibitor of p53 
transcriptional activity [14]). Accordingly with previous 
results [13], in the present work, the treatment of yeast 
cells expressing wt p53 with 5 µM PFT-α reduced the wt 
p53-induced growth inhibition by 68.0 ± 1.1% (n = 4). 
Additionally, in the presence of 5 µM PFT-α, 10 µM 
SLMP53-1 increased the wt p53-inhibitory effect by only 
5.8 ± 0.8% (n = 4; relative to PFT-α only). A similar result 
was obtained with yeast cells expressing mut p53R280K. 
In fact, in these cells, 10 µM SLMP53-1 induced a mut 
p53 inhibitory effect of 2.5 ± 1.1% (n = 4; relative to 
PFT-α only). These results established a correlation 
between the activation of p53 transcriptional activity 
by SLMP53-1 and its cytotoxicity in yeast, since in the 
presence of a p53 transcriptional inhibitor, the activity of 
SLMP53-1 was abolished. 
Growth inhibitory effect of SLMP53-1 on wt 
p53- and mut p53R280K-expressing tumor cells 
is mediated by a p53-dependent cell cycle arrest 
and/or apoptosis
The growth inhibitory potential of SLMP53-1, and 
the contribution of the p53 pathway to its activity, were 
ascertained in p53+/+ and p53−/− HCT116 tumor cells. A 
significant difference between the GI
50
 (concentration 
for 50% of maximal growth inhibition) values obtained 
in p53+/+ (~16 µM) and p53−/− (~34 µM) HCT116 cells 
indicated an involvement of p53 in the growth inhibitory 
effect of SLMP53-1 (Figure 2A). Conversely, no 
significant differences were observed between the GI
50
 
values of PRIMA-1 in p53+/+ and p53−/− HCT116 cells 
(Figure 2A). In our experimental conditions, the GI
50
 value 
of PhiKan083 in HCT116 cells was higher than 150 µM. 
The SLMP53-1 growth inhibitory effect 
was associated with G0/G1-phase cell cycle arrest 
(Figure 2B), and apoptosis (Figure 2C) in p53+/+, but 
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not in p53−/−, HCT116 cells. The enhancement of PARP 
cleavage by 16 µM SLMP53-1 in p53+/+, but not in p53−/−, 
HCT116 cells further corroborated the activation of a p53-
dependent apoptotic pathway (Figure 2D). 
Consistent with the yeast results, SLMP53-1 also 
inhibited the growth of mut p53R280K-expressing 
MDA-MB-231 cells with a GI
50
 value similar to that 
obtained in HCT116p53+/+ cells (~16 µM; Figure 2E). 
Moreover, it presented a much lower growth inhibitory 
activity against mut p53Y220C-expressing HuH-7 cells 
(Figure 2E). When compared to PRIMA-1, SLMP53-1 
presented a higher potency in MDA-MB-231 cells, but 
was less potent against mut p53Y220C-expressing HuH-7 
cells (Figure 2E). In our experimental conditions, the GI
50
 
values of PhiKan083 in MDA-MB-231 and HuH-7 cells 
were higher than 150 µM. 
Figure 1: SLMP53-1 activates wt p53 and restores the wt-like activity to mut p53R280K in yeast. (A) Synthesis of 
SLMP53-1 and chemical structure of its enantiomer. (b) Immunoblots of human wt p53, mut p53R280K and mut p53Y220C expressed 
in yeast after 30 h incubation in selective induction medium (representative of three independent experiments). Graphical representation: 
increase of wt and mut p53R280K-induced growth inhibition by 10 μM SLMP53-1 and of mut p53Y220C-induced growth inhibition by 
50 µM PhiKan083, after 30 h; results were plotted setting as 1 the growth inhibitory effect of wt p53-expressing cells treated with DMSO 
only; data are mean ± SEM (n = 5). (c) Increase of wt and mut p53R280K-induced yeast cell cycle arrest by 10 μM SLMP53-1; data are 
mean ± SEM (n = 3). In B and C, values significantly different from DMSO only: *p < 0.05, **p < 0.01.
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Interestingly, in MDA-MB-231 cells, despite not 
interfering with cell cycle progression (Figure 2F), 16 µM 
SLMP53-1 stimulated cell death, as revealed by the 
increase of late apoptosis (Figure 2G) and PARP cleavage 
(Figure 2H).
SLMP53-1 selectively activates p53 
transcriptional activity and reestablishes mut 
p53R280K DNA binding ability
The effect of SLMP53-1 on wt p53 and mut 
p53R280K activity was investigated by analysis of the 
expression levels of proteins encoded by p53 target genes 
in HCT116p53+/+, HCT116p53−/−, and MDA-MB-231 cells. 
In HCT116p53+/+ cells, 16 µM SLMP53-1 
increased the p53, MDM2, p21, PUMA and BAX 
expression levels (Figure 3A). Instead, the levels 
of these proteins were not significantly changed in 
HCT116p53−/− cells treated with 16 µM SLMP53-1, 
supporting the p53-dependent activity of this molecule 
(Figure 3A). Additionally, 16 µM SLMP53-1 increased 
the mRNA levels of CDKN1A (p21) and TNFRSF10B 
(KILLER) in HCT116p53+/+ cells (Figure 3B). 
The selective activation of p53 transcriptional activity by 
SLMP53-1 was further reinforced by a dual-luciferase 
gene reporter assay using p53+/+ and p53−/− HCT116 
cells transfected with p21- or MDM2-luciferase reporter 
vectors. At 16 µM and 32 µM (2 × GI
50
), SLMP53-1 
increased the expression of the two p53 reporters in 
HCT116p53+/+ cells, while no effect was observed in 
HCT116p53−/− cells (Figure 3C). 
In MDA-MB-231 cells, 16 µM SLMP53-1 increased 
MDM2, PUMA and BAX protein levels, with no apparent 
increase of p53 protein levels (Figure 3D). The lack of 
mut p53 protein stabilization was already reported for 
other mut p53 reactivators, and has been attributed to a 
reestablishment of the MDM2-mediated p53 degradation 
[15]. Moreover, consistent with the lack of effect on cell 
cycle progression, 16 µM SLMP53-1 did not affect p21 
protein levels (Figure 3D). 
The restoration of mut p53R280K DNA binding 
ability by SLMP53-1 was assessed by TransAM DNA 
binding assay, using MDA-MB-231 cells. The results 
revealed a dose-dependent enhancement of the amount of 
p53 bound to DNA by SLMP53-1 relative to cells treated 
with DMSO only (Figure 3E). 
To further demonstrate that the SLMP53-1 effects 
were dependent on mut p53R280K in MDA-MB-231 cells, 
mut p53R280K was knocked-down by p53siRNA. In cells 
transfected with non-specific siRNA (siRNA-NS; control), 
16 µM SLMP53-1 increased the protein levels of PUMA, 
BAX and cleaved PARP, as observed in non-transfected 
cells (Figure 3F). As expected, these SLMP53-1 
effects were efficiently abolished by mut p53 silencing 
(Figure 3F). 
SLMP53-1 triggers a p53-dependent 
mitochondrial apoptotic pathway in wt p53- and 
mut p53R280K-expressing tumor cells
In HCT116p53+/+ and MDA-MB-231 cells, 16 µM 
SLMP53-1 led to mitochondrial membrane potential 
(∆ψm) dissipation and reactive oxygen species (ROS) 
generation (Figure 4A). Consistent with p53-dependence, 
these effects were not observed in 16 µM SLMP53-1-
treated HCT116p53−/− cells (Figure 4A). Additionally, in 
HCT116p53+/+ (Figure 4B) and MDA-MB-231 (Figure 4C) 
cells, 16 µM SLMP53-1 triggered BAX, wt p53 (Figure 4B) 
and mut p53R280K (Figure 4C) mitochondrial 
translocation, and led to cytochrome c (cyt c) release to 
cytosol (Figure 4B and 4C). Altogether, these results 
showed that SLMP53-1 induced a p53-dependent 
mitochondrial apoptotic pathway in both wt p53- and mut 
p53R280K-expressing tumor cells. 
SLMP53-1 inhibits the migration of wt p53- and 
mut p53R280K-expressing tumor cells
The results obtained in the wound healing assay showed 
that the GI
10
 concentration (4 µM) of SLMP53-1 reduced 
the migration of HCT116p53+/+ and MDA-MB-231 tumor 
cells (Figure 5A and 5B). These results were corroborated 
by the chemotaxis cell migration assay, in which the GI
25
 
concentration (7 µM) of SLMP53-1 led to over 50% 
reduction of HCT116p53+/+ cell migration compared to 
DMSO only (Figure 5C). A similar result was obtained with 
the constitutively more motile MDA-MB-231 cells treated 
with 16 µM SLMP53-1 (Figure 5C). These data showed that 
SLMP53-1 inhibited the in vitro migration of both wt p53- and 
mut p53R280K-expressing tumor cells. 
SLMP53-1 sensitizes wt p53- and mut 
p53R280K-expressing tumor cells to conventional 
chemotherapeutics in a p53-dependent manner
We investigated whether SLMP53-1 increased the 
sensitivity of HCT116p53+/+ and MDA-MB-231 tumor 
cells to conventional chemotherapeutics. For that, a low 
concentration of SLMP53-1, with no significant growth 
inhibitory effects (GI
10
 of 4 µM), was combined with 
increasing concentrations of doxorubicin and etoposide. 
In HCT116p53+/+ cells, SLMP53-1 showed synergistic 
effects with all tested concentrations of chemotherapeutics 
(Q > 1.15), although the most pronounced effects were 
obtained with doxorubicin (Figure 6A). Conversely, no 
synergistic effects were observed between SLMP53-1 and 
the chemotherapeutics in HCT116p53−/− cells (Figure 6B). 
As in HCT116p53+/+ cells, synergistic effects between 
SLMP53-1 and all tested concentrations of doxorubicin 
and etoposide were also observed in MDA-MB-231 
cells (Q > 1.15) (Figure 6C). Interestingly, pronounced 
synergistic effects between 4 µM SLMP53-1 and the 
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Figure 2: SLMP53-1 growth inhibitory effect in human wt p53- and mut p53R280K-expressing tumor cells is mediated 
by p53-dependent cell cycle arrest and/or apoptosis. (A) GI
50
 value of SLMP53-1 in HCT116 cells, after 48 h treatment; values 
significantly different: **p < 0.01. (b) Cell cycle, (c) Apoptosis and (d) PARP cleavage after 24 h with 16 µM SLMP53-1 in HCT116 cells. 
(e) GI
50
 value for SLMP53-1 in MDA-MB-231 (mut p53R280K) and HuH-7 (mut p53Y220C) cells, after 48 h treatment. (F) Cell cycle, 
(G) Apoptosis and (H) PARP cleavage after 24 h with 16 µM SLMP53-1 in MDA-MB-231 cells. In A–C and E–G, data are mean ± SEM 
(n = 3–4). In  A, B, C and G, values significantly different from DMSO only: *p < 0.05, **p < 0.01. In F, values are not significantly 
different from DMSO only: p > 0.05. In D and H immunoblots are representative of three independent experiments.
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Figure 3: SLMP53-1 reactivates the transcriptional activity of wt p53 in HCT116p53+/+cells and mut p53R280K, 
through reestablishment of its DNA binding ability, in MDA-MB-231 cells. (A) Protein levels of p53 target genes, and 
(b) gene expression of CDKN1A (p21) and TNFRSF10B (KILLER), after 24 h with 16 µM SLMP53-1 in HCT116 cells. In B, fold 
expression changes are relative to DMSO and correspond to mean ± SEM (n = 3). (c) p53 transcriptional activity after 16 h with 16 µM 
and 32 µM (2 × GI
50
) SLMP53-1 in HCT116 cells assessed by dual-luciferase gene reporter assay. Data are plotted as mean relative light 
units (RLU) ± SEM (n = 3); values significantly different from DMSO only: *p < 0.05, ***p < 0.001. (d) Protein levels of p53 target 
genes after 24 h with 16 µM SLMP53-1 in MDA-MB-231 cells. (e) DNA binding affinity of mut p53R280K after 24 h with 32 µM and 
48 µM (3 × GI
50
) SLMP53-1 in MDA-MB-231 cells; the signal obtained with DMSO only was set as 1; data are mean ± SEM (n = 3); 
values significantly different from DMSO only: ***p < 0.001. (F) PARP cleavage and protein levels of PUMA and BAX after 24 h with 
16 µM SLMP53-1 in mut p53R280K-silenced MDA-MB-231 cells. In A, D and F, immunoblots are representative of three independent 
experiments.
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Figure 4: SLMP53-1 triggers a p53-mediated mitochondrial apoptotic pathway in HCT116p53+/+ and MDA-MB-231 
cells. (A) Cells were treated with 16 µM SLMP53-1 for 8 h (HCT116 cells) or 16 h (MDA-MB-231 cells) in ∆ψm analysis, and for 
24 h in ROS analysis. Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) was used as positive control in ∆ψm; histograms are 
representative of three independent experiments; M
2
 cursor indicates the subpopulation analyzed. Graphical representation: increase in the 
percentage of cells with ∆ψm dissipation and ROS generation; values are mean ± SEM (n = 3). (b) and (c) Immunoblots of wt/mut p53, BAX 
and cyt c, in cytosolic and mitochondrial fractions of (B) HCT116p53+/+ and (C) MDA-MB-231 cells after 16 h with 16 µM SLMP53-1. 
In B and C, immunoblots are representative of three independent experiments.
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Figure 5: SLMP53-1 prevents the migration of HCT116p53+/+ and MDA-MB-231 cells. (A) HCT116p53+/+ and 
(b) MDA-MB-231 confluent cells treated with 4 µM SLMP53-1 (or DMSO only) were observed at different time-points in the wound 
healing assay. (c) Effects of SLMP53-1 on the migration of HCT116p53+/+ (7 µM for 24 h) and MDA-MB-231 (16 µM for 8 h) cells 
analyzed by the chemotaxis assay; the migratory cells were quantified by fluorescence signal, setting as 1 cells treated with DMSO only; 
data are mean ± SEM (n = 3); values significantly different from DMSO only: ***p < 0.001. 
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lowest tested concentrations of doxorubicin (0.19 µM) 
and etoposide (0.38 µM) were also evident regarding total 
apoptosis in MDA-MB-231 cells (Q > 1.15; Figure 6D). 
Altogether, these results show p53-dependent synergistic 
effects of SLMP53-1 with conventional chemotherapeutics. 
SLMP53-1 has no in vitro toxicity in  
non-tumorigenic cells 
The potential genotoxicity of SLMP53-1 was 
investigated using the cytokinesis-block micronucleus 
assay. At 16 µM, SLMP53-1 did not increase the number 
of micronuclei in lymphocytes when compared to DMSO 
only (Figure 7A). Additionally, 16 µM SLMP53-1 
induced only 5.6 ± 3.2% (n = 5) growth inhibition 
in non-tumorigenic MCF10A cells, showing that 
this concentration is not toxic to normal cells. 
Furthermore, unlike in tumor cells, in MCF10A cells, 
the growth inhibition induced by SLMP53-1 at GI
50
 
concentration (42.4 ± 2.9 µM, n = 5) was associated with 
G0/G1-cell cycle arrest (Figure 7B), but not with apoptosis 
(Figure 7C).
SLMP53-1 has potent in vivo antitumor activity 
with no evident toxicity
To evaluate the in vivo antitumor potential 
of SLMP53-1, mice xenograft models carrying 
HCT116p53+/+, HCT116p53−/−, or MDA-MB-231 
tumor cells were used. The results revealed that four 
intraperitoneal administrations (twice a week) of 50 mg/kg 
SLMP53-1 were highly effective, blocking the growth of 
HCT116p53+/+ tumors (Figure 7D) compared to control 
(vehicle). Most importantly, SLMP53-1 had no effect 
on HCT116p53−/− tumor xenografts, corroborating its 
p53-dependent antitumor activity (Figure 7D). Potent 
antitumor activity was also established for MDA-MB-231 
tumors, confirming the in vivo efficacy of SLMP53-1 
against mut p53R280K-expressing tumors (Figure 7D). 
No significant loss of body weight or morbidity signs were 
observed in treated mice compared to control, throughout 
the experimental period (Figure 7E).
Considering the common chemotherapeutic side 
effects, some primary toxicity signs potentially triggered 
by SLMP53-1 were investigated in Wistar rats. For 
that, the organs relative weight (trophism), as well as 
biochemical and hematological data were analyzed 
for three rat groups (saline, vehicle and SLMP53-1) 
(Supplementary Table 1). No differences between the 
three groups on relative weight of liver, kidneys, heart and 
lungs were observed. Concerning biochemical data, only 
a slight decrease of urea in the vehicle group compared 
to saline group, and a slight decrease of uric acid and 
albumin in the SLMP53-1 group compared to vehicle 
group were observed. Hence, no evident liver or kidney 
toxicity was detected in SLMP53-1-treated group. Finally, 
concerning hematological data, just a small increase on 
the reticulocytes number was observed in the vehicle 
group compared to saline group, with no alterations 
between the SLMP53-1 and vehicle groups. Altogether, no 
apparent toxic side effects were observed for SLMP53-1 
on the tissues most commonly affected by conventional 
chemotherapeutics.
In order to assess the proliferation and apoptotic 
status of tumors, immunohistochemistry and TUNEL 
staining were performed for tumor tissues (Figure 8). 
Both HCT116p53+/+ and MDA-MB-231 tumors, treated 
with SLMP53-1, showed low Ki-67-positive staining 
(indicative of a low proliferative status), when compared 
to tumors treated with vehicle (Figure 8). Additionally, a 
marked increase of BAX expression levels in SLMP53-1-
treated tumor tissues, compared to vehicle, was observed 
(Figure 8). In addition, a pronounced increase of nuclei 
DNA fragmentation upon SLMP53-1 treatment was 
observed (Figure 8). On the other hand, a uniform pattern, 
characterized by high levels of Ki-67 and low levels 
of BAX expression and DNA fragmentation, between 
HCT116p53−/− tumors treated with SLMP53-1 and vehicle 
was obtained (Figure 8).
dIscussIon
From the analysis of a chemical library of novel 
enantiopure tryptophanol-derived oxazoloisoindolinones 
[16], the small-molecule SLMP53-1 was identified as a 
new reactivator of wt p53 and mut p53R280K. Considering 
the relevance of the absolute stereochemical configuration 
of biologically active compounds, the enantiomer 
of SLMP53-1 was also synthesized (Figure 1A). 
Interestingly, this enantiomer was inactive in yeast and 
exhibited a much lower growth inhibitory effect against 
wt/mut p53 bearing tumor cells compared to SLMP53-1 
(data not shown). These results highlight the relevance 
of the stereochemistry at positions C-3 and C-9b for the 
activity of SLMP53-1. 
The activation of wt p53 and mut p53R280K 
(a DNA contact mutant without major structural 
alterations), associated with the absence of effect on 
structural mut p53Y220C, lead us to hypothesize some 
preference of SLMP53-1 for the wt-like conformation of 
p53. Further studies are underway to analyze the activity 
of SLMP53-1 on other mut p53s.
Contrary to PRIMA-1, SLMP53-1 showed a 
p53-dependent tumor growth inhibitory activity. In fact, 
the induction of cell cycle arrest and apoptosis, and the 
enhancement of p53 transcriptional activity by SLMP53-1 
in wt p53-expressing HCT116 tumor cells were 
completely abolished in p53-null HCT116 cells. In turn, 
SLMP53-1 showed a much higher cytotoxicity against 
mut p53R280K-expressing MDA-MB-231 cells than 
PRIMA-1 (with previously reported cytotoxicity against 
this tumor cell line [17]). In these tumor cells, SLMP53-1 
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Figure 6: SLMP53-1 sensitizes HCT116p53+/+ and MDA-MB-231 cells to the effects of etoposide and doxorubicin. 
(A–c) Effects of combined treatment with 4 µM SLMP53-1 (or DMSO only) and increasing concentrations of doxorubicin (Doxo) or 
etoposide (Etop) on tumor cell growth, after 48 h; data are mean ± SEM (n = 4); the percentage of cell growth achieved with SLMP53-1 
only was (A) 90.3% in HCT116p53+/+, (B) 99.8% in HCT116p53−/− and (C) 90.5% in MDA-MB-231 cells. (d) Effects of combined 
treatment with 4 µM SLMP53-1 (or DMSO only) and 0.19 µM doxorubicin or 0.38 µM etoposide on apoptosis after 48 h in MDA-MB-231 
cells. The percentage of apoptotic cells obtained with SLMP53-1 only was 0.2%; data are mean ± SEM (n = 3). In A, C and D, the Q values 
are represented; dotted line represents Q = 1.15. 
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Figure 7: SLMP53-1, with no apparent in vitro toxicity, has potent in vivo antitumor activity. (A) Genotoxicity of 16 µM 
SLMP53-1 by cytokinesis-block micronucleus (MN) assay after 72 h treatment in human lymphocyte cells. Cells treated with 1 μg/mL 
cyclophosphamide were used as positive control (C+); data are mean ± SEM (n = 3). (b) Cell cycle after 48 h with 42.4 µM SLMP53-1 
in MCF10A cells; data are mean ± SEM (n = 3). In A and B, values significantly different from DMSO only: ***p < 0.001. C. Apoptosis 
after 48 h with 42.4 µM SLMP53-1 in MCF10A cells; data are mean ± SEM (n = 3); no significant differences between SLMP53-1 and 
DMSO only: p > 0.05. (d) BALB/c nude mice carrying HCT116p53+/+, HCT116p53−/− or MDA-MB-231 xenografts treated with 50 mg/kg 
SLMP53-1 or vehicle (control); values significantly different from control mice: *p < 0.05, **p < 0.01, ***p < 0.001; representative 
pictures of control and SLMP53-1-treated tumors. (e) BALB/c mice body weight during SLMP53-1 treatment; no significant differences 
between control and SLMP53-1-treated mice: p > 0.05.
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restored the wt-like sequence-specific DNA binding ability 
to mut p53R280K, with subsequent up-regulation of p53 
target genes. Curiously, in mut p53R280K-expressing 
cells, the SLMP53-1-induced growth inhibition was only 
associated with apoptosis, and not with cell cycle arrest. 
These results highlight key genetic differences between 
tumor cells associated with distinct p53 status (wt/mut). 
The pathophysiological relevance of the 
mitochondrial p53 function on apoptotic cell death has 
been emphasized in several studies [18]. In response to 
stress, a fraction of p53 translocates to mitochondria, 
where it binds with Bcl-2 family proteins inducing 
mitochondrial outer membrane permeabilization 
(MOMP), cyt c release, and subsequent apoptosis [18]. 
Figure 8: SLMP53-1 decreases cell proliferation and enhances apoptosis in human xenograft tumors. Representative 
images of Ki-67, BAX and DNA fragmentation detection in human HCT116p53+/+, HCT116p53−/− and MDA-MB-231 xenograft tumor 
tissues inoculated in BALB/c nude mice treated with 50 mg/kg SLMP53-1 or vehicle (Scale bar = 50 μm; Magnification 400 ×).
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The mitochondrial function of mut p53 is still unclear. 
Interestingly, mut p53 has been reported to localize 
constitutively at mitochondrial outer membrane due to 
its intrinsic cellular stabilization. Despite this, the mut 
p53 apoptotic activity is compromised by its inability to 
bind to Bcl-2 and trigger MOMP [18, 19]. In this work, 
SLMP53-1 triggered a mitochondrial p53 apoptotic 
pathway in wt p53-expressing tumor cells, involving ∆ψm 
dissipation, p53 and BAX mitochondrial translocation, 
as well as cyt c release. Similar events were triggered by 
SLMP53-1 in mut p53R280K-expressing tumor cells, 
supporting the translocation of a functionally active mut 
p53 to mitochondria. 
It is interesting to note that SLMP53-1 treatment 
induced a p53-dependent ROS generation, which may 
result from the stimulation of both pro-oxidant and 
mitochondrial p53 functions. Actually, SLMP53-1 
enhances the expression of BAX and PUMA, which 
besides a connection with the p53 mitochondrial pathway 
are also strongly involved in its pro-oxidant function [20]. 
Collectively, the results obtained indicate that 
SLMP53-1 is a “double hit” reactivator of p53-mediated 
apoptosis, stimulating both the transcription-dependent 
and mitochondrial-mediated p53 functions. 
Considered the main cause of morbidity and 
mortality in cancer patients, tumor cell invasion and 
metastization are central issues in cancer treatment 
[21, 22]. The pivotal role of p53 in the prevention of 
epithelial-mesenchymal transition and migration is widely 
recognized [22]. Accordingly, mut p53 has been associated 
to prometastatic functions not only due to the loss of p53 
function, but also to the GOF related to p63 inhibition, a 
well-known suppressor of tumorigenesis and metastasis 
[22]. Low doses of SLMP53-1 potently inhibited the 
migration of wt/mut p53-expressing cells, which sustains 
the reactivation of wt p53, as well as of mut p53 through 
reestablishment of its wt function and possible inhibition 
of its GOF. 
Drug combination may minimize drug side effects, 
while increasing tumor suppressor activity [23]. Since 
the majority of conventional chemotherapeutics, as 
etoposide and doxorubicin, depend on a functional p53 
pathway, combination with p53 reactivators is expected 
to enhance their efficacy. Indeed, at low doses, SLMP53-1 
showed p53-dependent synergistic effects with both 
chemotherapeutic agents in wt/mut p53-expressing 
tumor cells. Therefore, combination of SLMP53-1 with 
chemotherapeutics revealed great therapeutic potential, 
particularly against multidrug-resistant tumor cells, like 
triple-negative breast cancers.
The toxicity of standard chemotherapeutics remains 
a therapeutically limiting problem. Herein, SLMP53-1 
was shown to be non-genotoxic. Additionally, despite 
activating wt p53, at the GI
50
 concentration obtained in 
tumor cells, SLMP53-1 was not cytotoxic against wt 
p53-expressing normal MCF10A cells. The minimal 
cytotoxic effects of p53 reactivators on normal cells have 
been attributed to their lower susceptibility to apoptotic 
stimuli when compared to tumor cells with a constitutive 
activation of a DNA damage signaling pathway [24–26]. 
This leads normal cells to respond to p53 reactivators with 
cell cycle arrest (cytostatic effect), instead of cell death 
(cytotoxic effect) [27, 28]. Actually, this was observed in 
normal cells with SLMP53-1 at 3 × GI
50
 concentration 
used in tumor cells. SLMP53-1 can thus be exploited in 
p53-based cyclotherapy, in which normal cells are 
protected from the cytotoxicity of chemotherapeutics by 
induction of cell cycle arrest. 
Assays in xenograft mice models reinforced the 
p53-dependent in vivo antitumor activity of SLMP53-1. 
In fact, SLMP53-1 potently suppressed the growth of 
wt p53- and mut p53R280K-expressing tumors through 
inhibition of proliferation and induction of apoptosis, 
without interfering with the growth of p53-null tumors. 
Additionally, SLMP53-1 had no apparent toxic side effects 
on tissues most commonly affected by chemotherapy, such 
as kidneys, liver and bone marrow.
In conclusion, several evidences are provided in 
this work supporting the anticancer therapeutic potential 
of SLMP53-1, both alone and combined with conventional 
chemotherapeutics. To our knowledge, this is the first 
report of a pharmacological reactivator of mut p53R280K. 
Besides its potential applicability in cancer therapy, 
SLMP53-1 is a starting point for the development of new 
effective derivatives targeting mut p53s. 
MATeRIALS AND MeTHoDS
Chemical synthesis of SLMP53-1 and its 
enantiomer
All reagents and solvents were obtained from 
commercial suppliers and used without further 
purification. Melting point was determined using a Kofler 
camera Bock monoscope M. The infrared spectra were 
collected on a Shimadzu IRAffinity-1 FTIR infrared 
spectrophotometer. Only noteworthy IR absorptions 
(cm−1) are listed. Microanalyses were performed in a 
Thermo Scientific TM FLASH 2000 Series CHNS/O 
analyzer and are within ± 0.5% of theoretical values. 
Analysis Merck Silica Gel 60 F254 plates were 
used as analytical thin layer chromatography; flash 
chromatography was performed on Merck Silica 
Gel (200–400 mesh). Optical rotations were determined in 
a Perkin–Elmer 241 MC polarimeter at rt. 1H and 13C NMR 
spectra were recorded on a Bruker 400 MHz Ultra-Shield. 
1H nuclear magnetic resonance spectra were recorded at 
400 MHz. Carbon nuclear magnetic resonance spectra 
were recorded at 100 MHz. 1H and 13C NMR chemical 
shifts are reported in δ (ppm) referenced to the solvent 
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used and the proton coupling constants J in hertz (Hz) 
(Supplementary Figure 1). Spectra were assigned using 
appropriate COSY, DEPT and HMQC sequences.
Chemical Synthesis of SLMP53-1 (Figure 1A): 
2-Acetyl-benzoic acid (0.19 g, 1.16 mmol, 1.1 eq.) was 
added to a stirred solution of (S)-tryptophanol (0.2 g, 1.05 
mmol, 1.0 eq.) in 10 mL of toluene. The mixture was 
heated at reflux under inert atmosphere using Dean-Stark 
conditions during 16 h. The solvent was removed under 
reduced pressure and the residue obtained was purified by 
flash chromatography (Ethyl Acetate/n-Hexane 2:1). The 
product was obtained as a white solid (81% yield) after 
recrystallization in Ethyl Acetate/n-Hexane. SLMP53-1: 
IR (KBr): 3283 (N-H); 1697 (C = O) cm−1; mp: 182 – 
184 °C; [α]20
D




); 1H NMR 
(DMSO-d
6
) δ 10.92 (s, 1H, NH), 7.74 – 7.65 (m, 3H, 
H-Ar), 7.59 (m, 2H, H-Ar), 7.38 – 7.34 (m, 2H, H-Ar), 
7.08 (t, J = 7.1 Hz, 1H, H-Ar), 7.01 (t, J = 7.4 Hz, 1H, 
H-Ar), 4.41 – 4.29 (m, 2H, CH and OCH
2
), 4.14 (dd, 
J = 8.0, 6.1 Hz, 1H, OCH
2
), 3.25 (dd, J = 14.5, 5.1 Hz, 
1H, CH
2
-indole), 3.12 (dd, J = 14.6, 8.1 Hz, 1H, CH
2
-
indole), 1.67 (s, 3H, CH3); 
13C NMR (DMSO-d
6
) δ 173.76 
(C = O), 147.55 (Cq), 136.63 (Cq), 133.93 (CH-Ar), 
131.40 (Cq), 130.81 (CH-Ar), 127.85 (Cq), 124.04 (CH-
Ar), 123.87 (CH-Ar), 123.25 (CH-Ar), 121.49 (CH-Ar), 
118.86 (CH-Ar), 118.70 (CH-Ar), 111.88 (CH-Ar), 110.60 
(Cq), 98.87 (Cq), 74.65 (OCH
2
), 55.95 (CH), 30.84 (CH
2
), 
22.79 (CH3); Anal. calcd. for C20H18N2O2·0.15H2O: C 
74.81, H 5.67, N 8.73, found: C 74.86, H 5.67, N 8.75.
Chemical Synthesis of SLMP53-1 enantiomer 
(Figure 1A): Following the same procedure used 
for the synthesis of SLMP53-1, to a solution of 
(R)-tryptophanol (0.1 g, 0.53 mmol) in toluene (15 mL) 
was added 2-acetylbenzoic acid (0.10 g, 0.58 mmol). 
The product was obtained as a white solid (76% yield) 
after recrystallization in EtOAc/n-Hexane. [α]20
D
 −27.1 




) 1H NMR spectra was found to 
be identical to the one obtained for compound SLMP53-1.
Plasmids and compounds
The yeast expression vector pLS89-(TRP1) encoding 
human wt p53 under GAL1–10 inducible promoter 
(kindly provided by Dr. Richard Iggo; Swiss Institute 
for Experimental Cancer Research, Switzerland), and 
pTS76-(LEU2) encoding human mut p53R280K or mut 
p53Y220C under ADH1 constitutive promoter (kindly 
provided by Dr. Gilberto Fronza; IST Istituto Nazionale 
per la Ricerca sul Cancro, Genoa, Italy), were used. 
PRIMA-1, doxorubicin and PFT-α were purchased 
from Sigma-Aldrich, Phikan083 from Tocris and etoposide 
from Calbiochem. All tested compounds were dissolved in 
dimethyl sulfoxide (DMSO; Sigma-Aldrich).
Yeast-based screening assay
Saccharomyces cerevisiae (strain CG379) was 
transformed using the standard lithium acetate method 
[8]. For expression of human proteins, cells (routinely 
grown in minimal selective medium) were diluted to 
0.05 OD
600
 in induction selective medium containing 2% 
(w/w) galactose, 1% (w/w) raffinose, 0.7% (w/w) yeast 
nitrogen base without amino acids from Difco, and a 
mixture of all the amino acids required for yeast growth 
(50 μg/mL) except leucine (for pTS76) or tryptophan 
(for pLS89). Cells transformed with the empty vector 
(pTS76 or pLS89) were used as control yeast. Yeast 
cells were incubated at 30°C under continuous orbital 
shaking (200 r.p.m.), in the presence of 0.1 – 50 μM of 
compounds or 0.1% DMSO only, for approximately 30 h 
(time required by control yeast, incubated with DMSO 
only, to achieve 0.4 OD
600
). In the experiments with PFT-α, 
yeast cells expressing wt/mut p53 were incubated with 
5 μM PFT-α alone and combined with 10 μM SLMP53-1, 
or DMSO only for approximately 30 h. Yeast growth was 
analysed by counting the number of colony-forming units 
(CFU), after 2 days incubation at 30°C, on Sabouraud 
Dextrose Agar from Liofilchem. 
Yeast cell cycle analysis
Yeast cell cycle progression was analyzed basically as 
described [29]. Briefly, 1 × 107 cells were fixed in 70% (v/v) 
ethanol, incubated with 250 µg/mL RNase A (Sigma-Aldrich) 
and 1 mg/mL Proteinase K (Sigma-Aldrich), followed by 
10 µM Sytox Green Nucleic Acid from Invitrogen and flow 
cytometry analysis.
Human cell lines and growth conditions
Human colon adenocarcinoma HCT116 cell line 
expressing wt p53 (HCT116 p53+/+) and its isogenic 
derivative in which full-length p53 has been knocked out 
(HCT116 p53−/−) were kindly provided by Dr. B. Vogelstein 
(The Johns Hopkins Kimmel Cancer Center, Baltimore, 
MD, USA); human breast cancer MDA-MB-231, human 
hepatoma HuH-7, and non-tumorigenic human breast 
epithelial MCF10A cell lines were from ATCC. All tumor 
cell lines were routinely cultured in RPMI-1640 medium 
with ultraglutamine from Lonza supplemented with 10% 
fetal bovine serum (FBS) from Gibco. MCF10A cell line 
was cultured in DMEM F12 from Lonza supplemented 
with MEGM SingleQuot Kit Suppl. & Growth Factors 
from Lonza. All cell lines were maintained in a humidified 
incubator at 37°C with 5% CO
2
.
Sulforhodamine B (SRB) assay
Human cell lines were incubated in 96-well plates, at a 
final density of 5.0 × 103 cells/well (for HCT116 and HuH-7 
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cell line), and of 1.0 × 104 cells/well (for MDA-MB-231 and 
MCF10A cell line), for 24 h. Cells were thereafter treated with 
serial dilutions of compound (from 1.85 to 150 μM) for 48 h. 
The effect of compounds on in vitro growth was analyzed using 
the SRB assay as described [10, 30]. The solvent (DMSO; 
maximum concentration used of 0.25%) was included as control. 
For combined treatments, HCT116 p53+/+, HCT116 
p53−/− and MDA-MB-231 cell lines were treated with the GI
10
 
concentration of SLMP53-1 (or DMSO only) and increasing 
concentrations of doxorubicin (9.38 – 750 nM) or etoposide 
(0.38 – 6.00 µM). The effect of combined treatments on 
cell growth was analyzed after 48 h incubation, using the 
SRB assay, and is expressed by the combination index 
(Q), calculated as reported [30], which indicates: Q < 0.85, 
antagonism; 0.85 < Q < 1.15 additive effect; Q > 1.15, synergy.
Analysis of cell cycle and apoptosis in human cell lines
HCT116, MDA-MB-231 and MCF10A cell lines 
were incubated in 6-well plates, at a final density of 1.5 × 105 
cells/well (for HCT116 cell line) and 2.3 × 105 cells/well (for 
MDA-MB-231 and MCF10A cell lines), for 24 h. Cells were 
thereafter treated with SLMP53-1 or DMSO only for 24 h. For 
cell cycle analysis, cells were stained with propidium iodide 
(PI; Sigma-Aldrich) followed by flow cytometric analysis, as 
described [30]. For apoptosis analysis, cells were analyzed 
by flow cytometry using the Annexin V-FITC Apoptosis 
Detection Kit I from BD Biosciences according to the 
manufacturer’s instructions; synergistic effects of combined 
treatments between the GI
10
 concentration of SLMP53-1 (or 
DMSO only) and 0.19 µM doxorubicin or 0.38 µM etoposide, 
in MDA-MB-231 cell lines, were analyzed (determination of 
Q value) as described in the SRB assay.
Western blot analysis
Whole protein extracts (from yeast and human 
cells), and mitochondrial/cytosolic fractions from human 
cell lines were prepared as described [30]. Western blot 
analysis was performed as described [30] using a mouse 
monoclonal anti-p53 (DO-1), anti-MDM2 (SMP14), 
anti-BAX (2D2), anti-PUMA (B-6), anti-PARP (C2–10), 
and anti-cytochrome c (A8) antibodies followed by an 
anti-mouse horseradish-peroxidase (HRP)-conjugated 
secondary antibody. For p21 detection, membranes 
were probed with a rabbit polyclonal anti-p21 (C–19) 
antibody, followed by an anti-rabbit HRP-conjugated 
secondary antibody. For loading control, membranes 
were stripped and reprobed with a mouse monoclonal 
anti-yeast phosphoglycerate kinase (Pgk1p) or anti-GAPDH 
(6C5) antibodies. For analysis of mitochondrial and 
cytosolic fractions, membranes were reprobed with 
the loading controls mouse monoclonal anti-COX IV 
(F-8) and anti-GAPDH (6C5) antibodies, respectively. 
With the exception of anti-Pgk1p (Alfagene), all antibodies 
were purchased from Santa Cruz Biotechnology. Western 
blots presented are representative of three independent 
experiments.
Dual-luciferase reporter assay in human tumor 
cell lines
Dual-luciferase reporter assay was performed 
basically as reported [29, 31]. Briefly, about 5 × 104 
cells/well of HCT116 tumor cell line were incubated in 
24-well plates for 24 h. Cells were thereafter transfected 
at approximately 80% confluence using the Myrus LT-1 
reagent, and according to the manufacturer’s instructions. 
Specifically, 350 ng of the reporter vectors containing 
either the p21 (pGL3-1138) or the MDM2 (pGL3-MDM2) 
promoter were used along with 50 ng of the control 
pRLSV40 plasmid introduced to normalize the transfection 
efficiency. After transfection, cells were treated with the 
GI
50
 and 2 × GI
50
 concentration of SLMP53-1 (or DMSO 
only), for 16 h. Cells were harvested, and the luciferase 
assay was carried out using the dual-luciferase reagent. 
The p53 transcriptional activity is directly proportional 
to the luciferase activity (measured by the emitted light 
intensity) as described [29].
RNA extraction and quantitative RT-PCR (qPCR)
Total RNA from tumor cell lines was extracted using 
the RNeasy Kit (Qiagen). About 1 µg of RNA was used for 
cDNA synthesis using M-MuLV reverse transcritptase and 
RevertAid cDNA Synthesis kit (ThermoFisher) in 20 μL 
final volume, and following manufacturer’s instructions. 
qPCR assays were performed in a 384-well plate format 
on a CFX Touch Real-Time PCR Detection System 
(Bio-rad), starting with 25 ng of cDNA, as previously 
described [32]. The 2X KAPA SYBR® FAST qPCR Kit 
(Kapa Biosystems) and specific primers, purchased from 
Eurofins (MWG), were employed. GAPDH, B2M and 
ACTB were used as reference genes.
TransAM assay
About 1.5 × 106 cells of MDA-MB-231 cell 
line were incubated in T-75 flasks for 24 h. Cells were 
thereafter treated with 2 × GI
50
 and 3 × GI
50
 concentration 
of SLMP53-1 (or DMSO only) for 24 h. Nuclear protein 
extracts were obtained using the Nuclear Extract Kit from 
Active Motif, and the protein concentration was measured 
using NanoDrop 1000 from Thermo scientific. The p53 
DNA binding ability was evaluated using the TransAM p53 
Transcription Factor Assay Kit from Active Motif, 
according to the manufacturer’s instructions. Briefly, 
equal amount of total nuclear protein was loaded into a 
96-well plate coated with an immobilized oligonucleotide 
containing a p53 consensus binding site. The amount 
of bound p53 protein was quantified using an anti-p53 
antibody followed by a HRP-conjugated secondary 
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antibody. The HRP signal was measured after addition 
of a manufacturer’s substrate, using the Bio-Tek Synergy 
HT plate reader at 450 nm. A nuclear extract of wt 




 was used 
as kit positive control. 
Transfection of p53 siRNA
MDA-MB-231 cells were transfected with 100 nM 
of small interfering RNAs (siRNAs) against p53 
(SMARTpool p53) and negative nonspecific siRNAs 
(Non-targeting Pool) from Thermo Scientific/Dharmacon 
using Lipofectamine 2000 (Invitrogen), following the 
manufacturer’s instructions. After 24 h transfection, 
cells were treated with GI
50 
concentration of SLMP53-1 
(or DMSO only) for 24 h.
Analysis of ∆ψ
m
 dissipation and RoS generation
Analyses of ∆ψm dissipation and ROS generation 
were performed as previously reported [30]. Briefly, about 
1.5 × 105 cells/well (for HCT116 cell line) and 2.3 × 105 
cells/well (for MDA-MB-231 cell line) were incubated in 
6-well plates for 24 h. Cells were thereafter treated with 
the GI
50
 concentration of SLMP53-1 (or DMSO only) for 
8 h (for HCT116 cell line) or 16 h (for MDA-MB-231 cell 
line) in ∆ψm analysis, and for 24 h in ROS analysis. Then, 
cells were stained with 5 μM Cell-ROX Green Reagent 
from Life Technologies (in ROS analysis) or with 1 nM 
DiOC
6
(3) from Alfagene (in Δψm analysis) for 30 min at 
37ºC; followed by flow cytometry analysis.
In vitro migration assays 
Cell migration was analyzed using the Wound 
Healing Scratch assay (as described in [33]) and the QCM 
24-Well Fluorimetric Chemotaxis Cell Migration Kit 
(8 µm), from Merck Millipore. In the Wound Healing 
Scratch assay, about 5 × 105 cells/well of HCT116 p53+/+ and 
MDA-MB-231 cell lines were grown to confluence in 6-well 
plates for 24 h. Using a sterile 200 μL tip, a fixed-width 
wound was created in the cell monolayer and the GI
10
 
concentration of SLMP53-1 (or DMSO only) was 
added to medium. Cells were thereafter photographed 
using the Moticam 5.0MP camera with Motic’s AE2000 
inverted microscope with 400x magnification at different 
time-points of treatment until complete closure of the 
wound. In the QCM 24-Well Fluorimetric Chemotaxis 
Cell Migration Kit (8 μm), about 0.5 × 106 cells/mL 
of HCT116 p53+/+ and MDA-MB-231 cell lines were 
prepared in serum free RPMI 1640 treated with the GI
25
 
(for HCT116 p53+/+ cell line) or GI
50
 (for MDA-MB-231 
cell line) of SLMP53-1 (or DMSO only), and incubated 
for 24 h or 8 h, respectively. The prepared cell suspensions 
were distributed in 24-well plates (300 μL/insert), 
followed by addition of 500 μL medium containing 10% 
FBS to the lower chamber. Cells that migrated through 
the 8 μm pore membranes were eluted, lysed and stained 
with a green-fluorescence dye that binds to cellular nucleic 
acids. The number of migrated cells is proportional to the 
fluorescence signal measured using the Bio-Tek Synergy 
HT plate reader at 480/520 nm (ex/em). 
Genotoxicity studies by micronucleus assay
Genotoxicity was analyzed by cytokinesis-block 
micronucleus assay in lymphocytes as described [34]. 
Fresh peripheral blood samples were collected from healthy 
volunteers into heparinized vacutainers. Blood samples, 
suspended in RPMI medium supplemented with 10% FBS, 
were treated with the GI
50
 concentration of SLMP53-1, 
DMSO only or 1 μg/mL cyclophosphamide (known 
mutagenic agent; positive control; Sigma-Aldrich) for 44 h. 
Cells were thereafter treated with 3 μg/mL cytochalasin B 
(cytokinesis preventive; Sigma-Aldrich) for 28 h. 
Lymphocytes were isolated by density gradient separation 
(Histopaque-1077 and -1119; Sigma-Aldrich,), fixed in 
3:1 methanol/glacial acetic acid, and stained with Wright 
stain (Sigma-Aldrich). For each sample, 1000 binucleated 
lymphocytes were blindly scored using a Leica light optical 
microscope (Wetzlar); the number of micronuclei per 1000 
binucleated lymphocytes was recorded.
In vivo antitumor and toxicity assays
Animal experiments were conducted according to 
the European Council Directives on Animal Care and 
to the National Authorities. The BALB/c Nude mice 
and Wistar rats were purchased from Charles-River 
Laboratories and housed under pathogen free conditions 
in individual ventilated cages. For toxicity assays, Wistar 
rats were treated with 50 mg/kg SLMP53-1, vehicle 
(DMSO) or saline solution (control) by intraperitoneal 
injection, twice a week during two weeks. After the 
four administrations, samples of blood and organs 
(kidneys, liver, heart and lungs) were collected for 
toxicological analysis. Each group was composed of five 
animals. Xenograft tumor assays were performed with 
HCT116p53+/+, HCT116p53−/− and MDA-MB-231 human 
tumor cell lines. Briefly, 1 × 106 HCT116 cells (in PBS) or 
5 × 106 MDA-MB-231 cells (in PBS/BD Matrigel Matrix 
High Concentration, 1:1; BD Biosciences) were inoculated 
subcutaneously in the dorsal flank of each mice. Tumor 
dimensions were assessed by caliper measurement 
and their volumes were calculated [tumor volume 
= (length × width2) / 2]. Treatment was started when 
tumors reached volumes of approximately 100 mm3 
(which occurred 14 days after the grafts). Mice were 
then treated twice a week with 50 mg/kg SLMP53-1 or 
vehicle (control) by intraperitoneal injection during two 
weeks. Tumor volumes and body weights were monitored 
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twice a week until the end of the treatment. Animals were 
sacrificed by cervical dislocation at the end of the study. 
After sacrifice, tumors were removed and photographed. 
Human endpoints were established namely euthanasia 
in case of tumors reached 1500mm3, or if the animals 
presented any signs of morbidity. The following number of 
animals was used: HCT116p53+/+ and HCT116p53−/− cell 
lines (Control-6, Treatment-6), MDA-MB-231 (Control-6, 
Treatment-6).
Immunohistochemistry
Tumor tissues were fixed in 10% formalin, 
embedded in paraffin, sectioned at 4 µm, and stained with 
hematoxylin and eosin (H & E) or antibodies, following 
standard methodologies. Briefly, after deparaffination and 
rehydration, antigen retrieval was performed by boiling 
the sections for 20 min in 10 mM citrate buffer (pH 6.0). 
The slices were then held for 20 min at room temperature. 
After dewaxing and blocking the endogenous peroxidases 
with UltraVision Hydrogen Peroxide Block, sections 
were treated with UltraVision Protein Block solution, 
both from Lab Vision Thermo Scientific. Incubation with 
primary anti-Ki-67 (SP6) and anti-BAX (6A7) antibodies, 
from Pierce Thermo Scientific, was performed for 2 h, 
at room temperature. Immunostaining was carried out 
using the UltraVision Quanto Detection System HRP 
DAB kit, from Lab Vision Thermo Scientific, according 
to the manufacturer’s instructions. Tissue sections were 
counterstained with Gill’s hematoxylin from Thermo 
Scientific, dehydrated, clarified and mounted. The 
primary antibody was replaced by 10% non-immune 
serum for negative controls. Finally, images were 
obtained using the Motic’s AE2000 inverted microscope 
(400 × magnification) with the Moticam 5.0 MP camera.
TUNeL assay
TUNEL assay was performed using the in situ Cell 
Death Detection Kit Fluorescein from Roche, according to 
the manufacturer’s instructions. Briefly, after deparaffination 
and rehydration, tissues sections were treated for 20 min in 
10 mM citrate buffer (pH 6.0) and incubated with TUNEL 
Reaction Mixture for 60 min at 37°C in the dark. Tissues 
were counterstained with DAPI (0.1 μg/mL). Images were 
obtained using an Eclipse E400 fluorescence microscope 
(Nikon), 400 × magnification, with a Digital Sight camera 
system (Nikon DS-5Mc), carrying built-in software for 
image acquisition (Nikon ACT-2U).
Flow cytometric data acquisition and analysis
For the flow cytometric analysis, the AccuriTM C6 
flow cytometer from BD Biosciences and the CellQuest 
software from BD Biosciences were used. For the 
identification and quantification of cell cycle phases the 
FlowJo software was used.
Statistical analysis
Data were analyzed statistically using the GraphPad 
software. Differences between means were tested for significance 
using the Student’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001).
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